[2] The Centre, based at the Translational Research Institute and the Princess Alexandra Hospital, spans the spectrum of discovery of new therapeutic targets and their preclinical and clinical development.
She completed a Ph.D, in Cell Biology from the Australian National University's John Curtin School of Medical Research in 1990.
[4] Intellectual property from Nelson's research has been licensed from University of British Columbia to OncoGenex Pharmaceuticals, a Vancouver-based biotechnology company.
Her laboratory made the seminal discovery that castrate resistant prostate tumours can synthesize their own androgens de novo from cholesterol.
Recently, these findings have been extended to investigate the inter-relationships of androgen synthesis, prostate cancer progression, and metabolic syndrome.